摘要
目的分析急性脑梗死治疗药物的疗效和成本,以促进合理用药。方法选择急性脑梗死住院患者126例,在一般内科治疗相同的条件下分为依达拉奉组和胞磷胆碱组,并运用药物经济学方法统计分析。结果分别以总有效率与神经功能缺损评分减少率为效果指标时,胞磷胆碱组的增量成本-效果比分别为709.05和129.81。结论以总有效率为效果指标时,胞磷胆碱组更经济;以神经功能缺损评分减少率为效果指标时,依达拉奉组较合理。
Objective To evaluate the effect and economic cost of the drug therapy in acute cerebral infarction for promoting rational drug use. Methods 126 inpatients in our hospital with acute cerebral infarction were randomly divided into 2 groups. On the condition of the same general treatment, group A and group B were given edaravone and citicoline respectively. The curative effect and cost of two therapies were compared and analyzed with pharmacoeconomic cost- effectiveness method. Results With the total efficiency rate and the percent reduction of neural function deficits as the effect index, the incremental cost-effectiveness ratio （AC/AE） of two therapeutic schemes were 706. 50 and 129.81 respectively. Conclusion With the total efficiency rate as the effect index, eiticoline is superior to conservative therapy. While with the percent reduction of neural function deficits as effect index, edaravone is more reasonable.
出处
《中国药业》
CAS
2010年第3期39-40,共2页
China Pharmaceuticals
关键词
急性脑梗死
成本-效果
分析
acute cerebral infarction
cost - effectiveness
analysis
